Akero Therapeutics, Inc. — Director's Dealing 2020

Jan 22, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2020-01-16

Reporting Person: Versant Venture Capital VI, L.P. (10% Owner)
Reporting Person: Versant Ventures VI GP, L.P. (10% Owner)
Reporting Person: Versant Ventures VI GP-GP, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-16	Common Stock	S	22489	$19.72	Disposed	3129741	Indirect
2020-01-17	Common Stock	S	11103	$20.09	Disposed	3118638	Indirect
2020-01-21	Common Stock	S	8091	$21.78	Disposed	3110547	Indirect
2020-01-21	Common Stock	S	17849	$22.39	Disposed	3092698	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2: These sales were executed in multiple trades at prices ranging from $19.67 to $19.86. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F3: These sales were executed in multiple trades at prices ranging from $19.79 to $20.18. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F4: These sales were executed in multiple trades at prices ranging from $21.01 to $22.00. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F5: These sales were executed in multiple trades at prices ranging from $22.02 to $22.81. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F6: These shares are owned directly by Versant VI. Versant GP LP is the general partner of Versant VI and Versant GP LLC is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein.